This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands
by Zacks Equity Research
Veracyte's (VCYT) fourth-quarter 2023 performance reflects solid financial discipline and the strength of the Decipher Prostate and Afirma tests.
Best Income Stocks to Buy for February 23rd
by Zacks Equity Research
AROC, JSAIY and CAH made it to the Zacks Rank #1 (Strong Buy) income stocks list on February 23, 2024.
New Strong Buy Stocks for February 23rd
by Zacks Equity Research
IRDM, JSAIY, CAH, LNTH and CENTA have been added to the Zacks Rank #1 (Strong Buy) List on February 23, 2024.
ICON (ICLR) Q4 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) solid performance in the fourth quarter reflects continued market leadership across customer segments it serves.
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
by Zacks Equity Research
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
by Zacks Equity Research
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y
by Zacks Equity Research
Robust revenues from Exact Sciences' (EXAS) Screening and Precision Oncology segments contribute to the fourth-quarter top line.
Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.
Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down
by Zacks Equity Research
Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.
5 Stocks Favored by Brokers Amid the Current Uncertainty
by Maharathi Basu
We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.
Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?
by Zacks Equity Research
Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
by Zacks Equity Research
Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
Sight Sciences (SGHT) to Expand in Europe With New Launch
by Zacks Equity Research
By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.
Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract
by Zacks Equity Research
Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).
Globus Medical (GMED) Q4 Earnings Surpass, Margins Down
by Zacks Equity Research
Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.
Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.
GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility
by Zacks Equity Research
GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe
by Zacks Equity Research
In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.
SenesTech (SNES) Expands in the Netherlands With Q-chem Deal
by Zacks Equity Research
SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.